MannKind: Strategic Uncertainty Follows United Therapeutics' Pivot (Rating Downgrade) [Seeking Alpha]
MannKind Corporation (MNKD)
Last mannkind corporation earnings: 2/25 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.mannkindcorp.com/press-releases
Company Research
Source: Seeking Alpha
MNKD's valuation is challenged by rising operating expenses and the likely phase-out of its highest-margin revenue stream, despite a temporary revenue floor. Internal pipeline prospects, such as nintedanib DPI, offer potential but remain early-stage and unproven, while AFREZZA and FUROSCIX are unlikely to offset TYVASO DPI losses. I downgrade MNKD to 'Hold' due to limited near-term catalysts and unclear post-TYVASO DPI cash generation. Klaus Vedfelt/DigitalVision via Getty Images Overview MannKind's stock ( MNKD ) has tanked 48% since my " Buy " rating last October. The biopharma is in a bit of a quagmire. A key partner, United Therapeutics ( UTHR ), revealed its intention to seek approval This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am no
Show less
Read more
Impact Snapshot
Event Time:
MNKD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MNKD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MNKD alerts
High impacting MannKind Corporation news events
Weekly update
A roundup of the hottest topics
MNKD
News
- MannKind (MNKD) was downgraded by Zacks Research from "hold" to "strong sell".MarketBeat
- MannKind Corporation (MNKD) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]Seeking Alpha
- MannKind CEO purchases 100,000 shares; stock climbs [Seeking Alpha]Seeking Alpha
- MannKind to Present New Data From Pediatric and Adult Studies of Afrezza® at ATTD 2026 [Yahoo! Finance]Yahoo! Finance
- MannKind to Present New Data From Pediatric and Adult Studies of Afrezza® at ATTD 2026GlobeNewswire
MNKD
Earnings
- 2/26/26 - Beat
MNKD
Sec Filings
- 3/10/26 - Form 4
- 3/3/26 - Form 4
- 3/3/26 - Form 4
- MNKD's page on the SEC website